- •Chapter 1
- •Ocular Adnexal Lymphoproliferative
- •1.1 Pathogenesis
- •1.2 Chronic Antigen Stimulation
- •1.3 Immunosuppression
- •1.4 Pathology
- •1.5 Cytogenetics
- •1.6 Clinical Features
- •1.7 Imaging Findings
- •1.8 Staging
- •1.9 Positron Emission Tomography
- •1.10 Treatment
- •1.11 Follicular Lymphoma
- •1.12 Mantle Cell Lymphoma
- •1.13 Radiotherapy
- •1.14 Chemotherapy
- •1.15 Immunotherapy
- •1.16 Radioimmunotherapy
- •1.17 Outcome
- •1.18 The Future
- •References
- •Chapter 2
- •2.1 General Introduction
- •2.2 The Aging Process and Facial Analysis
- •2.3 Endoscopic Brow Lift
- •2.3.1 Introduction
- •2.3.2 Endoscopic Browlift Anesthesia Pearls
- •2.3.4 Endoscopic Browlift Postoperative Care Pearls
- •2.4 Upper Blepharoplasty
- •2.4.1 Introduction
- •2.4.2 Patient Evaluation
- •2.4.3 Upper Blepharoplasty Anesthesia Pearls
- •2.4.4 Upper Blepharoplasty Surgical Procedure Pearls
- •2.5 Lower Blepharoplasty, Fillers, and Midface Augmentation
- •2.5.1 Introduction
- •2.5.2 Patient Evaluation
- •2.5.3 Lower Blepharoplasty Anesthesia Pearls
- •2.5.4 Lower Blepharoplasty Surgical Procedure Pearls
- •References
- •Chapter 3
- •3.1 Introduction
- •3.2 What Is the Diagnosis?
- •3.2.1 Pitfalls of Diagnosis
- •3.2.2 A Diagnostic Corticosteroid Trial?
- •3.2.3 The Question of Biopsy
- •3.3 Treatment
- •3.3.1 Corticosteroids
- •3.3.2 Radiation
- •3.3.3 Other Agents
- •3.4 Special Circumstances
- •3.4.1 Pediatric IOIS
- •3.4.2 Sclerosing Pseudotumor
- •3.4.3 Tolosa–Hunt Syndrome
- •References
- •Chapter 4
- •4.1 Introduction
- •4.2 Embryology, Anatomy, Physiology, and Pathophysiology of the Canalicular System
- •4.3 Infective Causes
- •4.3.1 Periocular Herpes Simplex Infection
- •4.3.2 Bacterial Canaliculitis
- •4.4.1 Lichen Planus
- •4.4.2 Ocular Cicatricial Pemphigoid
- •4.5 Iatrogenic Causes
- •4.5.1 Systemic Drugs
- •4.5.1.2 Docetaxel (Taxotere)
- •4.5.2 Radiotherapy
- •4.5.3 Topical Ophthalmic Treatments
- •4.5.3.2 Mitomycin C (MMC) Therapy
- •4.5.4 Lacrimal Stents and Plugs
- •4.6 The Surgical Approach to Managing Canalicular Disease
- •4.6.1 Surgical Technique for Dacryocystorhinostomy with Retrograde Canaliculostomy
- •References
- •Chapter 5
- •5.1 Introduction
- •5.2 Nomenclature
- •5.3 Clinical Manifestations of NF1
- •5.4 Orbitofacial Tumors in NF1
- •5.4.2 Malignant Peripheral Nerve Sheath Tumors
- •5.4.3 Optic Pathway Gliomas
- •5.5 Genetics
- •5.5.1 The NF1 Gene
- •5.5.2 Overlapping NF1-Like Phenotype (SPRED1)
- •5.6.1 Introduction
- •5.7 Surgical Management of Orbitofacial Tumors in NF1
- •5.7.1 Introduction
- •5.7.2 Timing of Surgery
- •5.7.3 Periorbital Involvement
- •5.7.3.1 The Upper Eyelid
- •5.7.3.2 The Lower Eyelid and Midface
- •5.7.4 Orbital Involvement
- •5.7.4.1 Proptosis
- •5.7.4.3 Proptosis Due to Optic Nerve Glioma
- •5.7.4.4 Orbital Enlargement with Dystopia and Hypoglobus
- •5.8 The Natural History of NF1 Tumor Growth from Birth to Senescence
- •References
- •Chapter 6
- •6.1 Introduction
- •6.2 Surgical Anatomy of the Lacrimal Drainage System
- •6.3 Basic Diagnostics for Disorders of the Lacrimal Drainage System
- •6.4 Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy
- •6.5.1 Case A
- •6.5.2 Case B
- •6.5.3 Case C
- •6.5.4 Case D
- •6.5.5 Case E
- •6.5.6 Case F
- •6.5.7 Case G
- •References
- •Chapter 7
- •7.1 Introduction
- •7.2 Patients and Methods
- •7.2.1 Patients
- •7.2.2 Examination
- •7.3 Results
- •7.3.1 Patient Data
- •7.3.3 Family History
- •7.3.4 Pregnancy History
- •7.3.5 Birth
- •7.3.6 Associated Systemic and Ocular Diseases
- •7.3.8 Neuroradiological Findings (Brain MRI)
- •7.3.9 Nasolacrimal System Findings
- •7.4 Discussion
- •7.4.1 Patients
- •7.4.2 Obstetric and Family History
- •7.4.3 Associated Pathologies
- •7.4.3.1 Ophthalmological Findings in Unilateral Disease
- •7.4.3.2 Neuroradiological Findings
- •7.4.3.3 Systemic Diseases
- •7.4.3.4 Nasolacrimal Duct Findings
- •7.5 Conclusions
- •References
- •Chapter 8
- •8.1 Introduction
- •8.2 Evaluation of Complicated Ptosis
- •8.2.1 Compensatory Eyebrow Elevation
- •8.2.3 Innervation Patterns of the Frontalis Muscle
- •8.2.4 Checklist of Preoperative Evaluation of Complicated Ptosis
- •8.3 Surgical Technique of Levator Muscle Recession
- •8.3.1 Principle
- •8.3.2 Approach to the Levator
- •8.3.3 Partial Levator Recession
- •8.3.4 Total Levator Recession
- •8.3.6 Undercorrection and Overcorrection
- •8.4 Surgical Technique of Brow Suspension
- •8.4.1 Materials for Brow Suspension
- •8.4.1.1 Nonautogenous Materials
- •8.4.1.2 Autogenous Fascia Lata
- •8.4.2 Our Technique of Harvesting Autogenous Fascia Lata
- •8.4.3 Mechanical Principals of Brow Suspension
- •8.4.4 Upper Lid Approach
- •8.4.5 Fascia Implantation
- •References
- •Chapter 9
- •Modern Concepts in Orbital Imaging
- •9.1 Computerized Tomography
- •9.2 Three-Dimensional Imaging
- •9.3 Magnetic Resonance Imaging
- •9.3.1 The T1 Constant
- •9.3.2 The T2 Constant
- •9.3.3 Creating the MR Image
- •9.4 Imaging of Common Orbital Lesions
- •9.4.1 Adenoid Cystic Carcinoma
- •9.4.2 Cavernous Hemangioma
- •9.4.3 Dermoid Cyst
- •9.4.4 Fibrous Dysplasia
- •9.4.5 Lymphangioma
- •9.4.6 Lymphoma
- •9.4.7 Myositis
- •9.4.8 Optic Nerve Glioma
- •9.4.9 Pseudotumor
- •9.4.10 Rhabdomyosarcoma
- •9.6 Positron Emission Tomography
- •9.7 Orbital Ultrasound
- •9.7.1 Physics and Instrumentation
- •9.7.1.1 Topographic Echography
- •9.7.1.2 Quantitative Echography
- •9.7.1.3 Kinetic Echography
- •9.7.2 Extraocular Muscles
- •9.7.3 Optic Nerves
- •References
- •Chapter 10
- •10.1 Introduction
- •10.3 Etiology
- •10.4 Microbiology
- •10.5 Changing Pathogens and Resistance
- •10.5.2 Orbital MRSA
- •10.6 Evaluation of Orbital Cellulitis
- •10.7 Medical Treatment of Orbital Cellulitis
- •10.8 Surgical Treatment of Orbital Cellulitis
- •10.9 Prevention of Orbital Cellulitis After Orbital Fracture
- •References
- •Chapter 11
- •11.1 Clinical Picture
- •11.1.1 Clinical Phases
- •11.2 Ocular Complications
- •11.3 Investigation
- •11.3.1 Angiography
- •11.4 Management
- •11.4.1 Active Nonintervention
- •11.4.2 Indications for Treatment
- •11.5 Modalities of Treatment
- •11.5.1 Steroids
- •11.5.1.1 Topical Steroids
- •11.5.1.2 Intralesional Corticosteroid Injection
- •11.5.1.3 Oral Corticosteroids
- •11.5.2 Interferon-Alfa
- •11.5.3 Vincristine
- •11.5.4 Laser
- •11.5.5 Embolization
- •11.5.6 Surgery
- •References
- •Chapter 12
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Biological Behavior and Timing of Metastasis
- •12.4 Lateralization
- •12.5 Localization
- •12.6 Clinical Features
- •12.7 Imaging and Patterns of Orbital Metastatic Disease
- •12.8 Biopsy
- •12.9 Common Types of Orbital Metastases
- •12.9.1 Breast Carcinoma
- •12.9.2 Lung Carcinoma
- •12.9.3 Prostatic Cancer
- •12.9.4 Melanoma
- •12.9.5 Carcinoid Tumor
- •12.11 Treatment
- •12.11.1 Radiotherapy
- •12.11.2 Chemotherapy
- •12.11.3 Hormonal Therapy
- •12.11.4 Surgery
- •12.12 Prognosis and Survival
- •References
- •Chapter 13
- •13.1 Introduction
- •13.2 Rituximab
- •13.3 Yttrium-90-Labeled Ibritumomab Tiuxetan
- •13.4 Imatinib Mesylate
- •13.5 Cetuximab
- •References
- •Chapter 14
- •14.1 Introduction
- •14.2 Porous Orbital Implants
- •14.3 Orbital Implant Selection in Adults
- •14.4 Orbital Implant Selection in Children
- •14.5 Volume Considerations in Orbital Implant Selection
- •14.7 Which Wrap to Use
- •14.8 To Peg or Not to Peg Porous Implants
- •14.9 Summary
- •References
- •Chapter 15
- •15.1 Introduction
- •15.2 Etiology and Presentation
- •15.2.1 Etiology of Orbital Volume Loss
- •15.2.2 Etiology of Periorbital Volume Loss
- •15.2.3 Features of Orbital Volume Loss
- •15.2.4 Features of Periorbital Volume Loss
- •15.3 Background to Injectable Soft-Tissue Fillers
- •15.3.1 Historical Perspective on Volume Replacement
- •15.4 Types of Injectable Soft-Tissue Filler
- •15.4.1 Collagen Fillers
- •15.4.2 Hyaluronic acid Fillers
- •15.5 Treatment Areas
- •15.5.1 Orbit
- •15.5.2 Upper Eyelid and Brow
- •15.5.3 Tear Trough
- •15.5.4 Temple and Brow
- •15.6 Other Periorbital Uses of Injectable Soft-Tissue Fillers
- •15.6.1 Upper Eyelid Loading
- •15.6.2 Lower Eyelid Elevation
- •15.6.3 Treatment of Cicatricial Ectropion
- •15.7 Future Developments
- •References
Chapter 6 |
|
Clinicopathologic Features of Lesions |
|
A ecting the Lacrimal Drainage System |
6 |
in External Dacryocystorhinostomy |
Ludwig M. Heindl, Anselm G. M. Jünemann, and Leonard M. Holbach
Core Messages
■Differential diagnostic symptoms and signs in favor of a tumor of the lacrimal sac include a swelling above the medial canthal tendon, the presence of telangiectases in the skin overlying the mass, and the presence of serosanguinous discharge or a bloody reflux with atraumatic irrigation.
■All patients should be asked for a history of predisposing conditions, such as systemic diseases (e.g., lymphoma, Wegener granulomatosis, sarcoidosis) or neoplasms.
■External dacryocystorhinostomy (DCR) allows detailed inspection of the lacrimal sac and adequate tissue biopsy.
■Lacrimal sac biopsy should be considered selectively in patients with atypical clinical or intraoperative findings or in those with a history of predisposing systemic diseases.
■Biopsy results may help to define the degree of active specific inflammation requiring further chemoor immunotherapy postoperatively.
■Selective lacrimal sac biopsy permits early diagnosis of potentially life-threatening malignant tumors to determine further definitive management.
6.1 Introduction |
|
loma, mixed-cell papilloma, oncocytoma) and malignant |
|
(squamous cell carcinoma, transitional cell carcinoma, |
|
|
|
|
Disorders of the lacrimal drainage system (Table 6.1), |
adenocarcinoma, mucoepidermoid carcinoma, oncocytic |
|
which cause epiphora, punctal discharge, or medial can- |
adenocarcinoma) tumors [6, 9, 10, 17–19]. Mesenchymal |
|
thal swelling, are common ophthalmic complaints com- |
tumors such as fibrous histiocytoma, fibroma, heman- |
|
prising approximately 3% of clinic visits in some series |
gioma, hemangiopericytoma, angiosarcoma, or lipoma |
|
[8, 21]. The most common histopathologic findings in |
are less common (14%), and the rarer tumors include |
|
primary acquired nasolacrimal duct obstruction include |
lymphomas (8%), malignant melanomas (4%), and neu- |
|
chronic inflammation and fibrosis leading to occlusion |
ral tumors (1%) (Table 6.2) [6, 9, 10, 17–19]. Secondary |
|
of the lacrimal drainage system [7, 12, 13]. Secondary |
tumors originating in adjacent structures (paranasal |
|
causes of dacryostenosis may be the result of neoplasms, |
sinuses, orbit, nose) may extend into the lacrimal sac [6, |
|
systemic inflammatory diseases, infections, or trauma |
9, 10, 17–19]. Metastatic neoplasms confined to the lacri- |
|
[2, 19]. |
|
mal sac are extremely rare, and most metastases also |
Neoplasms that affect the lacrimal drainage system are |
affect adjacent structures, such as the eyelid, nose, sinuses, |
|
rare, but potentially life-threatening, so early diagnosis |
and orbit [6, 9, 10, 17–19]. |
|
and treatment are particularly important [17, 23]. Almost |
Inflammatory lesions, including nonspecific chronic |
|
500 primary lacrimal sac tumors have been reported and |
inflammation (“pseudotumor”) or granulomatous dis- |
|
were malignant in about 55% of the cases [6, 9, 10, 17–19]. |
ease, are not true neoplasms but may present as lacrimal |
|
Epithelial neoplasms are most common (73%), including |
sac masses and may be a sign of systemic diseases that |
|
benign (squamous cell papilloma, transitional cell papil- |
require further medical treatment [6, 17–19]. |
|
96 |
6 Clinicopathologic Features of Lesions A ecting the Lacrimal Drainage System |
Table 6.1. Differential diagnosis of lacrimal drainage disorders
Punctal causes of epiphora
– Congenital punctal atresia
6– Punctal ectropion in eyelid malposition
–Acquired punctal stenosis due to age-related atrophic processes, chronic inflammation, cicatricial conjunctival disease, systemic chemotherapeutic agents
Canalicular causes of epiphora
–Congenital absence or fistula
–Acquired intrinsic disorders: postherpetic infection (herpes simplex, varicella zoster); bacterial infection (e.g., Actinomyces, Chlamydia); trauma; postirradiation; pharmacological; intrinsic tumor (e.g., squamous papilloma, squamous cell carcinoma)
–Acquired extrinsic disorders: compression or invasion and occlusion by adjacent tumor (e.g., basal cell carcinoma, squamous cell carcinoma, non-Hodgkin B-cell lymphoma)
Lacrimal sac causes of epiphora
–Congenital diverticulum or fistula (from sac to nose or cheek)
–Acquired intrinsic disorders: inflammation (extension of primary acquired nasolacrimal duct obstruction, including dacryoliths, Wegener granulomatosis, sarcoidosis, allergy, hay fever, atopy), trauma, intrinsic tumor arising within the sac or the sac walls (Table 6.2)
–Acquired extrinsic disorders: adjacent tumor compressing or invading the sac from the outside (e.g., basal cell carcinoma, squamous cell carcinoma, non-Hodgkin B-cell lymphoma, neurofibroma)
Nasolacrimal duct causes of epiphora
–Congenital nasolacrimal duct obstruction (delayed opening of valve of Hasner with or without dacryocele, craniofacial abnormality, rare nasolacrimal duct agenesis)
–Primary acquired nasolacrimal duct obstruction (most common cause in adults)
–Secondary acquired lacrimal obstruction, including trauma and tumors (as for sac and those extending from the maxillary sinus) Nasal causes of epiphora
–Allergic rhinitis, severe rhinosinus disease (e.g., polyps), previous nasal surgery
–Tumors spreading from nasal space or adjacent sinuses
Source: Adapted from [8]
Table 6.2. Lacrimal sac tumors
I.Epithelial tumors
1.Squamous cell papilloma
2.Transitional cell papilloma
3.Mixed-cell papilloma (exophytic or endophytic)
4.Oncocytic adenoma (oncocytoma)
5.Squamous cell carcinoma
6.Transitional cell carcinoma
7.Adenocarcinoma
8.Mucoepidermoid carcinoma
9.Oncocytic adenocarcinoma
II.Nonepithelial tumors
1.Fibrous histiocytoma
2.Pyogenic granuloma
3.Neurilemmoma
4.Lymphoid tumors
5.Malignant melanoma
6.Angiosarcoma
Source: Modified from [6]
The recognition and proper management of such lifethreatening lesions require an understanding of the anatomy and general diagnostic techniques of the lacrimal drainage system.
6.2Surgical Anatomy of the Lacrimal Drainage System
On lid closure, tears are wiped to the nasal bulbar conjunctiva and tear meniscus and are then drained through the superior and inferior lacrimal puncta, which are open only with open eyes, and canaliculi into the lacrimal sac and by a sort of “lacrimal peristalsis” into the nose (Fig. 6.1). The canaliculi start with a 2-mm vertical component and continue with a horizontal portion 8–10 mm long. The common canaliculus, 1–2 mm long, leads into the lacrimal sac. Its entry into the sac at the internal ostium is often partially covered by a mucosal flap, which is based anteriorly and also called “the valve of
6.4 Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy |
97 |
Fig. 6.1 Schematic illustration of the lacrimal drainage system with approximate measurements (Redrawn from [8])
Rosenmüller.” The lacrimal sac lies in the fossa between the anterior (frontal process of maxilla) and posterior (lacrimal bone) lacrimal crest and is surrounded by the anterior and posterior limbs of the medial canthal tendon. The body of the sac measures 10–12 mm in vertical height, and 3–5 mm of the sac (fundus) lie above the internal ostium. The suture line in the lacrimal fossa runs vertically between the thin lacrimal bone and the thicker frontal process of the maxilla. It is mostly located one half of the way from the anterior to the posterior lacrimal crest. The sac leads into the bony nasolacrimal duct, which measures 12–15 mm in length and travels within the wall of the maxillary sinus and the lateral nasal wall. The duct extends for about 5 mm below the bony portion and opens beneath the inferior turbinate in the lateral wall of the nose. A mucosal valve (Hasner) usually prevents retrograde passage of mucus or air upward. The nasal entry site of a DCR lies at the anterior tip of the middle turbinate. The ethmoid sinus may extend to the lacrimal sac fossa. Bony removal of the lacrimal sac fossa may result in entry into the ethmoid sinus rather than into the nasal vault [8, 20].
6.3Basic Diagnostics for Disorders of the Lacrimal Drainage System
Prior to clinical examination, it is helpful to ask the patient for severity, duration, and quality of symptoms. The most common symptoms indicating dysfunction of the lacrimal drainage system include epiphora, punctal discharge, and medial canthal swelling. Epiphora is
typically worse in the winter months and windy weather. The eye can be sticky due to an expressible mucocele or collected dried tears. The vision can be blurred secondary to an elevated tear meniscus (prismatic effect, especially on downgaze, for example, when reading) or tear-splat- tered glasses. Chronic epiphora can induce red, sore lower lid skin, with secondary anterior lamella (vertical) shortening (mild cicatricial ectropion). Excessive wiping away of tears can cause or exacerbate a medial ectropion.
Mucopurulent punctal discharge suggests stasis in the lacrimal sac or canaliculi, mostly secondary to nasolacrimal duct obstruction. Accumulation of inflammatory debris can result in dacryolithiasis in up to 15% of DCR surgeries. Lacrimal sac stones consist of dried mucus, lipid, and inflammatory cells and are more likely to be found in chronically inflamed sacs.
Medial canthal swelling may be caused by an abscess, a dacryolith, or a tumor in the lacrimal sac. But, not all masses in the medial canthal area arise from the lacrimal sac (acute skin infection, acute ethmoiditis, ruptured dermoid cyst). Swellings below the medial canthal tendon are typical of dacryocystitis. Differential diagnostic signs in favor of a tumor of the lacrimal sac include a mass above the medial canthal ligament (absent in dacryocystitis), the presence of telangiectases in the skin overlying the mass (instead of the diffuse erythema of dacryocystitis) and the presence of serosanguinous discharge or a bloody reflux with atraumatic irrigation (both of which are not usually observed in dacryocystitis).
All patients should be asked not only for their complaints, but also for the history of predisposing conditions, such as systemic diseases (e.g., lymphoma, Wegener granulomatosis, sarcoidosis), trauma, neoplasms, and dacryocystitis.
In addition to a comprehensive ophthalmic examination, particularly with regard to ocular surface disease and eyelid and punctum position, the assessment of the lacrimal drainage system must include inspection, palpation, digital expression of lacrimal sac contents, and standard irrigation and probing of the nasolacrimal system. Imaging studies (dacryocystography, computed tomography (CT), magnetic resonance imaging) are reserved for selected patients with atypical symptoms and signs. Detailed history taking and nasal endoscopy must be performed by an otorhinolaryngologist to rule out intranasal pathology [8].
6.4Selective Lacrimal Sac Biopsy in External Dacryocystorhinostomy
Although endonasal endoscopic DCR is gaining clinical popularity in the therapy of acquired dacryostenosis, the external DCR is regarded as the gold standard in terms of
|
|
98 |
6 Clinicopathologic Features of Lesions A ecting the Lacrimal Drainage System |
||
|
|
surgical success [4, 5, 14, 16]. In addition, the external |
of patients with and without lacrimal sac biopsy during |
||
|
|
approach allows an excellent possibility for inspection of |
external DCR. In our series of 421 consecutive patients |
||
|
|
the lacrimal sac (Fig. 6.2) and for biopsy (excisional |
undergoing external DCR with selective lacrimal sac |
||
|
or incisional |
with debulking) of abnormal-appearing |
biopsy, no significant difference was detectable |
||
6 |
|||||
findings. |
|
between patients with and without biopsy regarding |
|||
|
|
In view of lacrimal tumors mimicking symptoms and |
5-year overall survival. None of the patients without |
||
|
|
||||
|
|
signs of primary acquired nasolacrimal duct obstruction, |
biopsy developed clinical evidence of systemic inflam- |
||
|
|
some lacrimal surgeons perform “routine” lacrimal sac |
matory diseases (e.g., Wegener granulomatosis, sarcoi- |
||
|
|
biopsy during external or endonasal DCR [1, 3, 11–13, |
dosis) or neoplasms of the lacrimal drainage system |
||
|
|
15, 22]. Incidence rates for significant lacrimal sac pathol- |
within follow-up. |
||
|
|
ogies that require further medical or surgical interven- |
Our follow-up results are compatible with the findings |
||
|
|
tion varied between 0% and 14% of biopsy specimens |
of seven previously published series with routine lacrimal |
||
|
|
obtained routinely during DCR [1, 3, 11–13, 15, 22]. |
sac biopsy [1, 3, 11–13, 15, 22]. Here, only 7 of 1,294 speci- |
||
|
|
Since recent clinicopathologic studies revealed signifi- |
mens (0.5%) showed specific pathology that was definitely |
||
|
cant histopathologic findings only in clinically suspicious |
not suspected clinically, and only 1 of these (0.08%) was |
|||
|
cases [3, 11, 15], we suggest selective lacrimal sac biopsy |
found to be malignant (lymphoma) [1, 3, 11–13, 15, 22]. |
|||
|
during external DCR only for patients with atypical clini- |
Using selective lacrimal sac biopsy only in patients |
|||
|
cal or intraoperative findings rather than routine biopsy |
with atypical clinical or intraoperative findings, positive |
|||
|
of all patients with primary acquired nasolacrimal duct |
biopsy results could be found in 3.8% of 442 consecutive |
|||
|
obstruction. |
|
external DCR procedures: primary non-Hodgkin B-cell |
||
|
|
If lacrimal sac biopsy is not performed in all cases of |
lymphoma (mucosa-associated lymphoid tissue, MALT) |
||
|
primary acquired nasolacrimal duct obstruction, the |
in one patient, secondary bilateral non-Hodgkin B-cell |
|||
|
risk of overlooking significant pathologies that require |
lymphoma (MALT) in one patient, squamous cell carci- |
|||
|
further medical or surgical intervention should be kept in |
noma in two patients, malignant melanoma in one |
|||
|
mind. Therefore, we compared the long-term follow-up |
patient, oncocytoma in one patient, pyogenic granuloma |
|||
|
|
|
|
in three patients, Wegener granulomatosis in three |
|
|
|
|
|
patients (one bilateral), and sarcoidosis in two patients |
|
|
|
|
|
(one bilateral) (Table 6.3). |
|
|
|
|
|
Our results are compatible with the pooled data of |
|
|
|
|
|
seven previously published series with routine lacrimal |
|
sac biopsy [1, 3, 11–13, 15, 22] revealing significant pathology in 50 of 1,294 specimens (3.9%). In detail, significant lacrimal sac pathology was detected in 2 of 14 specimens (14.3%) in Linberg and McCormick’s series (one sarcoidosis, one leukemia) [12]; in 4 of 162 specimens (2.5%) in Tucker et al.’s series (two lymphoma, one sarcoidosis, one oncocytoma) [22]; in 10 of 302 specimens (3.3%) in Bernardini et al.’s series (four sarcoidosis,
Fig. 6.2 External DCR allows an excellent possibility for inspection of the lacrimal sac and for taking biopsy samples of abnormal-appearing findings
Table 6.3. Results of selective lacrimal sac biopsies
Histopathology |
No. of cases (% total) |
|
Non-Hodgkin B-cell lymphoma |
3 |
(18%) |
(MALT) |
|
|
Squamous cell carcinoma |
2 |
(12%) |
Malignant melanoma |
1 |
(6%) |
Oncocytoma |
1 |
(6%) |
Pyogenic granuloma |
3 |
(18%) |
Wegener granulomatosis |
4 |
(24%) |
Sarcoidosis |
3 |
(18%) |
